Finish Line in Sight:
SARcode Launches Pivotal Study of SAR 1118 in Dry Eye
By Marie Powers
Thursday, September 15, 2011
Privately held SARcode Bioscience Inc. has enrolled the first patient in OPUS-1, its pivotal Phase III trial of topical SAR 1118 ophthalmic solution. OPUS-1 will study the safety and efficacy of SAR 1118 in the treatment of dry eye.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.